STERIS plc

Good morning, everyone, and welcome to the Staris PLC fourth quarter 2025 conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touchdown phones. To withdraw your questions, you may press star and two. As you all know, today's event is being recorded. At this time, I'd like to turn the floor over to Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations.

Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Investor Relations. Julie Winter, Any redistribution, retransmission, or rebroadcast of this call without the express written consent of Staris is strictly prohibited. Some of the statements made during this review are, or may be considered, forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in Staris's securities filing. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. Staris' SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow, will be used. Additional information regarding these measures, including definitions, is available in our release, as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. With those cautions, I will hand the call over to Mike.

Thank you, Julie, and good morning, everyone. It is once again my pleasure to be with you this morning to review the highlights of our fourth quarter performance from continuing operations. For the fourth quarter, total as reported revenue grew 4%. Constant currency organic revenue grew 6% in the quarter, driven by volume as well as 210 basis points of price. Gross margin for the quarter increased 170 basis points compared with the prior year to 44.3%. Positive price, favorable mix, and productivity outpaced labor inflation. EBIT margin increased 110 basis points to 24.8% of revenue compared with last year. The adjusted effective tax rate in the quarter was 23.5%. The year-over-year increase was driven by unfavorable discrete item adjustments. Net income from continuing operations in the quarter was $270 million. Adjusted earnings per diluted share from continuing operations was $2.74, a 14% increase over the prior year. We are pleased with our ability to grow earnings double digits all year with lower interest expense following the divestiture of the dental segment. Capital expenditures for fiscal 2025 totaled $370 million, while depreciation and amortization totaled $476 million. We continue to pay down debt during the quarter, ending with $2 billion in total debt. Gross debt to EBITDA at quarter end was approximately 1.4 times. Free cash flow for fiscal 2025 was a record $787 million, well above our full-year guidance, driven by significant working capital improvements, in particular inventory. With that, I'll turn the call over to Dan for his remarks.

Thanks, Mike, and good morning, everyone. Thank you for joining us to hear more about our fiscal 2025 performance and our outlook for fiscal 2026. Mike covered the quarter, so I will touch on our performance for the full year and our outlook for fiscal 2026. From a total company perspective, we ended the year with 6% revenue growth and 12% earnings growth. The diversified nature of our business allowed us to deliver results in line with our original outlook, despite a few obstacles during the year. Looking at our segments, healthcare constant currency organic revenue grew 6% for the year, led by strong recurring revenue streams. Our outperformance in consumables and services continues to be driven by procedure volumes in the U.S., as well as price and market share gains. Healthcare capital equipment revenue declined 5% for the year against our record year last year. Capital equipment orders grew over 12% for the full year, as underlying demand remained strong. Margins improved nicely in healthcare, hitting the 25% mark for the year, with volume, pricing, and positive productivity offsetting labor inflation. Towards the end of the year, we also began to benefit from the restructuring cost savings, capturing approximately $5 million in savings in the fourth quarter of fiscal 2025. Turning to AST. Constant currency organic revenue grew 9% for the year, with 7% growth in services. Med device customers remained stable, while bioprocessing was a bit lumpy during the year. Capital equipment shipments more than doubled compared to the prior year and exceeded our expectations. EBIT margins for AST were 44.8%, down slightly year over year as we continued to face energy and labor headwinds and had a negative mixed shift from capital equipment shipments. Constant currency organic revenue increased 1% for life sciences for the full year, driven once again by strong growth in consumables and services offset by a decline in capital equipment revenue. Margins increased to 42.3%, a 360 basis point improvement benefiting from favorable mix, pricing, and the divestiture of the CECS business. From an earnings perspective, We ended the year strong and exceeded our revised outlook with adjusted EPS of $9.22. The upside to our estimates was driven by lower corporate spending and improved profitability in both healthcare and the life science segments. Turning to our outlook for fiscal 2026, as noted in the press release, we anticipate as reported revenue from continuing operations to grow six to 7% in fiscal 2026. We do not have any acquisition or divestiture impacts heading into the new fiscal year, and changes in foreign currency are expected to be neutral to Staris. As a result, constant currency organic revenue growth is also expected to grow six to seven percent. Included in this outlook is approximately 200 basis points of price. Each segment is expected to grow revenue in the range of six to seven percent for fiscal 2026. One minor note on AST revenue growth. Our outlook reflects high single-digit growth in services revenue, which will be somewhat offset by a decline in capital equipment to get to the 6% to 7% growth total for the year. As you saw in the press release, we have estimated the impact for tariffs for fiscal 2026, which are reflected in our outlook. We manufacture a significant number of products in North America for use in the U.S. with about 85% of the products sold in the U.S. coming from North American manufacturing. This significantly reduces our tariff exposure compared to many others. But we are not immune to the impact of tariffs. Our fiscal 2026 outlook of $9.90 to $10.15 includes $30 million of tariff costs. The EPS range implies 7% to 10% growth in earnings, including tariffs, which is impressive performance. I want to take a moment to thank our supply chain and commercial teams for all their efforts on this front. The anticipated tariff impact is a net number. We do expect to leverage the strength of Staris to mitigate some of our exposure. The $30 million estimate is based on global tariffs currently in effect, including the 10% global tariff and the recently announced 90-day trade deal with China. For your modeling purposes, at the high end of our earnings range, we would expect EBIT margins to increase approximately 20 basis points, reflecting our ability to offset tariffs. The effective tax rate is planned at approximately 23.5%. As we enter into the new fiscal year, we are well positioned to deliver both top and bottom line growth in 2026. That concludes our prepared remarks for the call. Julie, would you please give the instructions so that we can begin the Q&A?

Thank you, Mike and Dan, for your comments. Jamie, can you please give the instructions for Q&A and we'll get started.

Ladies and gentlemen, at this time, we'll begin that question and answer session. To ask a question, you may press star and then one on your touch-tone phones. If you are using a speakerphone, we do ask that you please pick up your handset prior to pressing the keys to ensure the best sound quality. To withdraw your questions, you may press star and two. Again, that is star and then one. to join the question queue. And our first question today comes from Dave Dracali from Citizens. Please go ahead with your question.

Hey, good morning and congrats on the quarter and the year. I guess we're looking at the segments, you know, the biggest implied delta is and then that life sign and I was just curious to get some color on your comfort in that kind of bouncing back to that 6% to 7% range.

Yeah, we did extremely well this year in our recurring revenues, especially our chemistries and consumables business, and we would expect that to continue. Where we were down significantly was obviously capital equipment. With a lot of uncertainty in pharma, the orders just dried up in the first half of the year. However, we saw a really strong rebound late in the year, and we are coming into fiscal 2026 with a pretty good backlog and a pretty good rate of orders, so we're confident we'll be able to deliver the bulk of those in fiscal 2026. and continue on with the growth that we've seen historically within our consumables business.

Great. One quick follow-up. It seems like the tariff impact might be, I don't know, 24 cents or something like that on the EPS line, yet you're still getting into a double-digit range at the high end. I guess if you could just talk about some of the puts and take, maybe even on the interest expense. I know you've delivered a bunch, but... you know, to get to that, even despite the tariffs, just maybe some color there.

Yeah, Dave, this is Mike. So as normal, there's quite a bit of headwinds or tailwinds or puts and takes. First and foremost, we are going to benefit from about $20 million of restructuring cost savings that will be in FY26. So that's a good guy. In addition to that, we do not anticipate spending $20-plus million in ETO litigation. We anticipate spending about $5 million, so there's $15 million to the good also. But offsetting that is incentive comp getting back to 100% bonus. That is a negative $15 million. Obviously, the tariffs are another negative $15 million. And then if you look at our lower interest expense, is really going to offset our higher tax rates. So that's just the reconciliation for FY26 of the puts and takes.

Thank you.

You're welcome.

Our next question comes from Mike Matson from Needham & Company. Please go ahead with your question.

Yeah, thanks. So just Your cash flow guidance is a little bit down from 25. I know you called out the working capital improvement you saw in 25. I mean, is that the main kind of differential between the two years?

The big thing, Mike, is we anticipate paying a $40 million legal settlement for ETO, which is NFY 26, so that's going to negatively impact cash by $40 million. And, of course, we are not anticipating... to overachieve or reduce inventory as dramatically as we had in FY25. But the big difference is the ETO legal fees, plus the impact of tariffs will negatively impact free cash flow also.

Okay, got it. And then just, you know, your leverage ratio is down quite a bit. So, you know, just maybe you can give us an update on M&A. You know, I'd expect you'd probably be looking to do some more deals if you can find things, but

Yeah, I mean, this is Dan. What I would say, Mike, is that we have the capacity both from a financial perspective and from an intellectual perspective at this point, having not done any meaningful M&A now for a few years. So if the right opportunity presents itself, you know, we'll be involved.

Okay, thank you. Our next question comes from Patrick Wood from Morgan Stanley.

Please go ahead with your question.

Awesome. Thanks, Sigmund. Just two quick ones. It's probably too early to say, but, you know, how the conversations with the customers been around potentially like onshoring back to the U.S.? I'm trying to think of, you know, I know some of the outsourced contract manufacturers have seen like, you know, a big pickup and people trying to pull production back. I'm just curious, is that something that you think is actually going to happen or is it more just a nice bullet point on a McKinsey slide?

It's probably the latter. But I do think there is some opportunities. I assume you're talking about MedTech in particular, but I do think there are some opportunities. Many of those large companies have manufacturing for local regions, and to the extent that they may be manufacturing in Europe for the U.S., and they have U.S.-based manufacturing for similar products, you may see some shift of volumes going forward. you know, east or west, depending on the benefit that they can do in terms of tariff and how easy it is to do it. Keep in mind, highly regulated industry, you know, it's not easy to move production volumes if they don't have all the regulatory permits and things like that. So it takes time, but there'll be some fluidity to it, I'm sure.

That's awesome. And then just like quickly around the kind of that M&A angle again, you know, what have you been hearing from some of the smaller players, you know, niche app compliance costs, all those sorts of things? Is there a situation where, you know, I know EO capacity is tight, but is there a situation where they end up having to force sell themselves essentially to you guys or your peers? Like, how do you think about industry consolidation on the back of the kind of one-off costs there?

I mean, in a general sense, I do think there'll be some industry consolidation, but, you know, we'd be in a much better position green-fielding than we would be buying assets that are 30-plus years old.

I mean, I'm 40, so I take offense at that, but thanks, guys.

Well, you've been compliant your whole life.

That's definitely not true.

Our next question comes from Matt Etop from Stevens, Inc. Please go ahead with your question.

Hey, good morning. I'll add my congrats in the quarter and the year as well. Maybe just touching on the outlook for FY26, you commented on AST kind of coming in line with 6% to 7% growth for the year, low single digits for capital equipment, high single digits for services. But can you flush out what you're seeing within the respective customer bases there? I think there's a little bit of a delta between what maybe I and the streetwear expecting versus your internal expectations. So if you could just provide a little color there, that'd be great.

Yeah, you know, I think what we're doing here is we've seen a lot of just movement month to month, quarter to quarter in terms of volume. It has started to sort of modulate down. But, you know, our view is let's take a little more conservative approach on how aggressively some of the bioprocessing is going to recover and also how as customers reassess where they're manufacturing and if there is any movement going on and what implications that may have on total volume.

Got it. And then just in light of like the current macro and everything that's going on with general policy, is there power conversations progressing with clients? Have there been any change in behaviors relating to life sciences or the AST segment?

Nothing that I would point to. There's a number of discussions, but I can't say there's anything concrete.

Thank you for taking my questions. Appreciate it. Sure thing. Our next question comes from Michael Polark from Wolf Research.

Please go ahead with your question.

Hey, good morning. Maybe two on health care. The first one, the allusion to market share gains driving growth in the fiscal year and quarter. I know we've talked about this before, but is there any service or business line that really stands out to you there as to Starris doing way better than market? If so, what is it and what's going right?

Honestly, I would say it's just across the entire segment right now. Our teams are just doing a phenomenal job, in particular in the North American markets. We've just built out such a great portfolio of and enterprise solution for large systems around sterile processing in particular and all the services that go along with that that we continue to do really well.

And for the fiscal year ahead, 6% to 7% growth for the healthcare segment, would you call out any expected variances between how consumable services and equipment should grow in 2026?

No, we're not going to provide that level of granularity. I will hit back on the fact that we had a great order year that bodes well in terms of backlog for capital going in next year. So we're optimistic about that.

Thank you. Our next question comes from Jason Bednar from Piper Sandler.

Please go ahead with your question.

Hey, morning, everyone. Nice finish to the year here. Wanted to see if we could spend just maybe a bit more time on tariffs. Really topical for all companies here this quarter. Maybe break down, if you could, what that $30 million looks like across your network. I know you had $30 million in the press release, Mike. I think you made some comment at one point, I think early on, around $15 million, but just want to confirm it's $30 million net. And then, if possible, break down maybe, again, how much exposure you have here around, like, China-related tariffs and how much on the non-China side. It would just be helpful so we can update our own thinking as we see the next updates on the tariff front.

I mean, just, Dan, I'll let Mike add to this, but at a high level, it's about half China and half sort of the 10% global tariff, and it's about $30 million. No more to add on that.

All right. I like it. All right. I think you said that $30 million, again, is a net number. Are you assuming any mitigation actions in that $30 million figure? What does the pacing of that activity look like throughout fiscal 26? And then I'll just sneak in one extra here. It looks like share repo was a little lighter in the fourth quarter compared to the prior few quarters, but the stock's been hanging around a similar level now for some time, well off its highs. maybe just talk about the decision to pause some of that activity and is there a signal we should draw from that pause?

Yeah, I would say that, you know, in general, we had bought about $200 million of shares during FY25. Uh, we had bought those earlier in the year compared to the previous year. I would say there's no signal that we're driving there. Uh, it is almost double that what we've typically bought just offset dilution and, uh, Obviously, with our debt levels and debt ratios being where they are, we would definitely consider doing additional share buybacks beyond our offsetting, just offsetting dilution in the future.

Sorry, on the mitigation activity on tariffs?

Yeah, the $30 million is a net number, Jason, so it's significantly higher than that. Obviously, there's a lot to be done. to mitigate. Timing is always the question. Obviously, our supply chain guys and girls are working very hard to offset as much as possible. But, yeah, it's a net number of 30, and we anticipate that that will hit us about equally throughout the calendar year.

I would just add to that, you know, with the 90-day pause or sort of redirect on the China tariffs, it gives us an opportunity to be much more strategic and thoughtful in terms of anything that we're changing as it relates to either vendors or manufacturing location or supply. So I would expect more weight on the back end.

And also, I don't think we've said this, more weight on health care. They're primarily impacting the health care segment with a little bit in life sciences.

And very, very little, if any, in ASTs.

All right, very good. Thank you, everyone. You're welcome.

Once again, if you would like to ask a question, please press star and then one. Our next question comes from Brett Fishman from KeyBank. Please go ahead with your question.

Hey, guys. Thank you very much for taking the questions, and good morning. Just wanted to ask another question on healthcare capital equipment. Sounds like you're not trying to give specific guidance on growth, but maybe just talk a little bit more about the capital equipment backdrop. You're exiting the year with some growth in the backlog, but really just curious how some of the recent macro developments have impacted either ordering patterns or hospitals' willingness to do implementations versus any deferrals you may be seeing.

We've talked about this a lot in the past, and that is the capital equipment that we offer is really more of a utility than a luxury item. If you're going to see procedural growth and migration of procedures to different places, you can't accommodate that growth without having sterile processing capacity or surgical suites. So at times when it may impact replacement business, if those things can be deferred, it doesn't really impact the new equipment in terms of going into expansion. So we had a great order year last year, growing orders 12%. We've got our backlog into a very comfortable position. We haven't seen anything at this point that would indicate that that's slowing for us. and in fact had really good volume in terms of orders going into the Q1. So we're excited about the opportunity there.

And then just as a follow-up, I'm going to switch gears a little bit to AST. I think it was a pretty good sequential progression in FY25 from an AST growth standpoint. Just looking at FY26, for services, it sounds like high single digits is kind of the starting point. I'm just curious if, like, demand were to be higher than expected, do you have enough capacity to theoretically, you know, return to double-digit growth in AST service, or is capacity starting to become, like, a little bit of a limiting factor? Thank you very much.

Sure. It's not a governor for us right now. We are well-positioned to accommodate the industry's growth.

And our next question is a follow-up from Michael Polark from Wolf Research. Please go ahead with your follow-up.

Thank you. Just one more also on AST. As you reflect on fiscal 25 in the services line, the December quarter was up 10%, March quarter up 6%. Dan, it sounds like file process is a little lumpy. Is that the gyration or anything else to kind of spike out on the phasing of the last 12 months that makes more sense to you? One other idea is any evidence that there was kind of front-loading of inventory building ahead of The Trump tariff era in the December quarter, could that have been an influence in that period? Any other color would be great. Thank you.

Sure. Yeah, no, we did not see that in terms of anybody front-loading tariff. I think you're giving the industry way too much credit to be able to see that coming. What I would say is we had a phenomenal December, an extraordinary December in terms of year-over-year comps. And then nobody showed up for the first seven days of January. So, you know, just the plant restarts, you know, from a customer perspective was very abnormally slow this year. You know, one day shorter of February in terms of processing days. And then we had a wonderful, you know, second half of February and March in terms of growth. But overall, those things impacted the quarter. I don't think it was any more than that.

Thank you.

And, ladies and gentlemen, with that, we'll conclude today's question and answer session. I'd like to turn the floor back over to management for any closing remarks.

Thanks, everybody, for taking the time to join us this morning. We look forward to catching up with many of you in the coming weeks.

And with that, ladies and gentlemen, we'll conclude today's conference call and presentation. We do thank you for joining. You may now disconnect your lines.